Design, synthesis, and biological evaluation of novel tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on optimized interactions with the enzyme's surface-exposed front region

Journal of Medicinal Chemistry

Volumn 51, Issue 14, 2008, Pages 4122-4149

  Laufer, Stefan A ^a   Hauser, Dominik R J ^a   Domeyer, David M ^a   Kinkel, Katrin ^a   Liedtke, Andy J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ADENOSINE TRIPHOSPHATE; AMINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLYCOGEN SYNTHASE KINASE 3BETA; IMIDAZOLE DERIVATIVE; INTERLEUKIN 1BETA; ISOENZYME; L 790070; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ML 3163; ML 3375; ML 3403; PROTEIN KINASE C ALPHA; PROTEIN KINASE LCK; PYRIDINE DERIVATIVE; SB 242235; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOLECULAR INTERACTION; QUANTUM YIELD; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HUMANS; IMIDAZOLES; MOLECULAR MIMICRY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47749104908     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701529q     Document Type: Article

References (76)

1. Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science (Washington, D.C.) 2004, 303 (5665), 1800-1805.
2. Chen, Z.; Gibson, T. B.; Robinson, F.; Silvestro, L.; Pearson, G.; Xu, B.; Wright, A.; Vanderbilt, C.; Cobb, M. H. MAP kinases. Chem. Rev. 2001, 101, 2449-2476.
3. Schieven, G. L. The biology of p38 kinase: a central role in inflammation. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005, 5, 921-928.
4. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
5. Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
6. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
7. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42, 2180-2190.
8. Wagner, G.; Laufer, S. Small molecular anti-cykotine agents. Med. Res. Rev. 2006, 26, 1-62.
9. Goldstein, D. M.; Gabriel, T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005, 5, 1017-1029.
10. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
11. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L.; Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 1997, 4, 311-316.
12. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhinisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
13. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; bdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
14. ClinicalTrials.gov. http://clinicaltrials.gov/ct/. 2007.
15. Dominguez, C.; Powers, D. A.; Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discovery Dev. 2005, 8, 421-430.
16. Dambach, D. M. Potential adverse effects associated with inhibition of p38a/b MAP kinases. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005, 5, 929-939.
17. Zhang, J.; Shen, B.; Lin, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci. 2007, 28, 286-295.
18. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Webb, E. F.; Hall, R.; Sorenson, M.; Lee, J. C.; Ayrton, A.; Griswold, D. E.; Gallagher, T. F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116.
19. Testa, B.; Jenner, P. Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab. Rev. 1981, 12, 1-117.
20. Tang, C.; Chiba, M.; Nishime, J.; Hochman, J. H.; Chen, I. W.; Williams, T. M.; Lin, J. H. Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome p450s. Drug Metab. Dispos. 2000, 28, 680-686.
21. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science (Washington, D.C.) 2002, 298, 1912-1916.
22. Hopkins, A. L.; Groom, C. R. Opinion: The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
23. Keri, G.; Orfi, L.; Eros, D.; Hegymegi-Barakonyi, B.; Szantai-Kis, C.; Horvath, Z.; Waczek, F.; Marosfalvi, J.; Szabadkai, I.; Pato, J.; Greff, Z.; Hafenbradl, D.; Daub, H.; Muller, G.; Klebl, B.; Ullrich, A. Signal transduction therapy with rationally designed kinase inhibitors. Curr. Signal Transduction Ther. 2006, 1, 67-95.
24. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996.
25. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
26. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
27. Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment. Expert Opin. Ther. Pat. 1997, 7, 571-588.
28. Traxler, P. Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin. Ther. Pat. 1998, 8, 1599-1625.
29. Sebolt-Leopold, J. S.; English, J. M. Mechanisms of drug inhibition of signalling molecules. Nature 2006, 441, 457-462.
30. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
31. Laufer, S. A.; Hauser, D. R. J.; Liedtke, A. J. Regiospecific and highly flexible synthesis of 1,4,5-trisubstituted 2-thioimidazoles from structural diverse ethanone precursors. Synthesis 2008, 2, 253-266.
32. Clark, M. P.; Laughlin, S. K.; Laufersweiler, M. J.; Bookland, R. G.; Brugel, T. A.; Golebiowski, A.; Sabat, M. P.; Townes, J. A.; VanRens, J. C.; Djung, J. F.; Natchus, M. G.; De, B.; Hsieh, L. C.; Xu, S. C.; Walter, R. L.; Mekel, M. J.; Heitmeyer, S. A.; Brown, K. K.; Juergens, K.; Taiwo, Y. O.; Janusz, M. J. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production. J. Med. Chem. 2004, 47, 2724-2727.
33. Laufer, S. A.; Zimmermann, W.; Ruff, K. J. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. J. Med. Chem. 2004, 47, 6311-6325.
34. Laufer, S. A.; Striegel, H.; Wagner, G. K. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. J. Med. Chem. 2002, 45, 4695-4705.
35. Peifer, C.; Wagner, G.; Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6, 113-149.
36. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 2003, 46, 3230-3244.
37. Kammerer, B.; Scheible, H.; Albrecht, W.; Gleiter, C. H.; Laufer, S. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}- (1-phenylethyl)-amine), a 4-pyridinylimidazole- type p38 mitogen-activated protein kinase inhibitor. Drug Metab. Dispos. 2007, 35, 875-883.
38. Kammerer, B.; Scheible, H.; Zurek, G.; Godejohann, M.; Zeller, K. P.; Gleiter, C. H.; Albrecht, W.; Laufer, S. In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS. Xenobiotica 2007, 37, 280-297.
39. Laufer, S.; Albrecht, W. ML3403 - Pharmacological characterization of a potent p38 MAP kinase inhibitor. Inflammation Res. 2004, 53 (Suppl. 3), S215.
40. McInnes, C.; Fischer, P. M. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. 2005, 11, 1845-1863.
41. Laufer, S. A.; Liedtke, A. J. A concise and optimized four-step approach toward 2-(aryl-)alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles using alkyl- or arylalkyl thiocyanates. Tetrahedron Lett. 2006, 47, 7199-7203.
42. Little, T. L.; Webber, S. E. A simple and practical synthesis of 2-aminoimidazoles. J. Org. Chem. 1994, 59, 7299-7305.
43. Dodson, R. M. Reaction of S-benzylisothiourea with phenacyl bromide. J. Am. Chem. Soc. 1948, 70, 2753-2755.
44. Dodson, R. M.; Ross, F. Preparation of 2-alkylthioimidazoles. J. Am. Chem. Soc. 1950, 72, 1478-1480.
45. Revesz, L. Thiazole and Imidazo[4,5-b]pyridine Compounds with MAP Kinase Inhibitory Activity and Their Pharmaceutical Use as Antiinflammatories and Immunosuppressants. 2000-EP10528[2001030778], 82, WO 25-10-2000, 2000 (Novartis A.-G., Switzerland, and Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.).
46. Laufer, S.; Wagner, G.; Kotschenreuther, D. Ones, thiones, and N-oxides: an exercise in imidazole chemistry. Angew. Chem., Int. Ed. 2002, 41, 2290-2293.
47. Ridge, D. N.; Hanifin, J. W.; Harten, L. A.; Johnson, B. D.; Menschik, J.; Nicolau, G.; Sloboda, A. E.; Watts, D. E. Potential antiarthritic agents. 2. Benzoylacetonitriles and b-aminocinnamonitriles. J. Med. Chem. 1979, 22, 1385-1389.
48. Golebiowski, A.; Townes, J. A.; Laufersweiler, M. J.; Brugel, T. A.; Clark, M. P.; Clark, C. M.; Djung, J. F.; Laughlin, S. K.; Sabat, M. P.; Bookland, R. G.; VanRens, J. C.; De, B.; Hsieh, L. C.; Janusz, M. J.; Walter, R. L.; Webster, M. E.; Mekel, M. J. The development of monocyclic pyrazolone based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2285-2289.
49. Wagaw, S.; Buchwald, S. L. The synthesis of aminopyridines: a method employing palladium-catalyzed carbon-nitrogen bond formation. J. Org. Chem. 1996, 61, 7240-7241.
50. Cho, Y. H.; Park, J. C. A very convenient dimethylamination of activated aromatic halides using N,N-dimethylformamide and ethanolamines. Tetrahedron Lett. 1997, 38, 8331-8334.
51. Erdmann, D. Einführung Polarer Reste in Seitenketten von Pyridin-C2-cycloalkyl-aminderivaten. Diploma Thesis, 2005; Merckle GmbH (a company of the ratiopharm group (Ulm)).
52. Hesse, M., Meier, H., Zeeh, B., Eds. Spectroscopic Methods in Organic Chemistry; George Thieme Verlag: Stuttgart, Germany, 1995; p 364
53. Forrer, P.; Tamaskovic, R.; Jaussi, R. Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities. Biol. Chem. 1998, 379, 1101-1111.
54. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 344, 135-137.
55. Linsenmaier, S. Entwicklung und Optimierung von in Vitro Testverfahren zur Evaluierung von Hemmstoffen der p38α MAP Kinase und JNK3. Ph.D. Thesis, University of Tuebingen, Tuebingen, Germany, 2006.
56. Friedrichs, A. Optimierung eines Vollblut-Testsystems zur Evaluierung von Hemmstoffen der Zytokin-Freisetzung. Diploma Thesis, University of Tuebingen, Tuebingen, Germany, 2005.
57. Klein, C. Validierung eines Vollblut-Assays zur Evaluierung von Hemmstoffen der Zytokin-Freisetzung. Diploma Thesis, University of Tuebingen, Tuebingen, Germany, 2006.
58. BDGentest Corp. http://www.bdbiosciences.com/. 2007.
59. UpstateTM. http://www.upstate.com. 2007.
60. Jank, H. N. S-2 Substituierte Thioimidazole als Inhibitoren der p38 MAP Kinase-Optimierung der Wechselwirkung zur Ribose/Phosphat-Bindungsstelle. Ph.D. Thesis, University of Tuebingen, Tuebingen, Germany, 2003.
61. Henry, J. R.; Rupert, K. C.; Dodd, J. H.; Turchi, I. J.; Wadsworth, S. A.; Cavender, D. E.; Schafer, P. H.; Siekierka, J. J. Potent inhibitors of the MAP kinase p38. Bioorg. Med. Chem. Lett. 1998, 8, 3335-3340.
62. Boehm, J. C.; Bower, M. J.; Gallagher, T. F.; Kassis, S.; Johnson, S. R.; Adams, J. L. Phenoxypyrimidine inhibitors of p38.alpha. kinase synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. Bioorg. Med. Chem. Lett. 2001, 11, 1123-1126.
63. Lisnock, J.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998, 37, 16573-16581.
64. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
65. Laughlin, S. K.; Clark, M. P.; Djung, J. F.; Golebiowski, A.; Brugel, T. A.; Sabat, M.; Bookland, R. G.; Laufersweiler, M. J.; VanRens, J. C.; Townes, J. A. The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-[alpha]) production. Bioorg. Med. Chem. Lett. 2005, 15, 2399-2403.
66. 1H NMR. J. Org. Chem. 2003, 68, 4527-4530.
67. Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discovery 2003, 2, 736-746.
68. Miwatashi, S.; Arikawa, Y.; Kotani, E.; Miyamoto, M.; Naruo, K.; Kimura, H.; Tanaka, T.; Asahi, S.; Ohkawa, S. Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3- thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J. Med. Chem. 2005, 48, 5966-5979.
69. Kuma, Y.; Sabio, G.; Bain, J.; Shpiro, N.; Márquez, R.; Cuenda, A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 2005, 280, 19472-19479.
70. Allegretti, M.; Berdini, V.; Cesta, M. C.; Curti, R.; Nicolini, L.; Topai, A. One-pot, new stereoselective synthesis of endo-tropanamine. Tetrahedron Lett. 2001, 42, 4257-4259.
71. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
72. FlexX, version 1.13; Tripos Inc.: St. Louis, MO, 2004; http://www.tripos.com/.
73. InsightII; Accelrys, Inc.: San Diego, CA, 2000; http://www.accelrys.com/.
74. Minor, J. T.; Hawkins, G. F.; VanderWerf, C. A.; Roe, A. Synthesis of 2- and 6-fluoronicotinamides. J. Am. Chem. Soc. 1949, 71, 1125-1126.
75. Stevens, K. L.; Jung, D. K.; Alberti, M. J.; Badiang, J. G.; Peckham, G. E.; Veal, J. M.; Cheung, M.; Harris, P. A.; Chamberlain, S. D.; Peel, M. R. Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors. Org. Lett. 2005, 7, 4753-4756.
76. 50 values vary by about ±20%.